Testing BR1400 drugs for essential hypertension in adults
Tests BR1400-1, BR1400-2, BR1400-3, BR1400-4 and BR1400-5 in adults with essential hypertension.
Key facts
- Who runs it
- Boryung Pharmaceutical Co., Ltd
- Where
- Soeul, South KoreaSee the site
- Trial code
- Registry title
- A Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 330 people, planned
- Started
- 1 Mar 2026
- Expected to end
- 1 Feb 2027
- Type of study
- Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- BR1400-1
- BR1400-2
- BR1400-3
- BR1400-4
- BR1400-5
- BR1400-A
- BR1400-B
- BR1400-C
- Record updated
- 28 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with essential hypertension (high blood pressure with no known other cause) to test how well and how safely new study drugs lower blood pressure.
- Age
- 19 years or older
- Sex
- Men and women can join.
- Disease stage
- Essential hypertension. At the first visit, the top blood pressure number (mean sitting systolic) must be 140 to under 180 mmHg without blood pressure treatment, or 130 to under 180 mmHg with treatment. At the second visit, 140 to under 180 mmHg, or 130 to under 180 mmHg with heart disease, diabetes with heart disease, albuminuria, or diabetes with chronic kidney disease.
- Earlier treatment
- People taking blood pressure medicine can join if the investigator finds it medically appropriate to stop it for a while during the study.
Main reasons for not taking part
- Top blood pressure number 180 mmHg or higher, or bottom number 110 mmHg or higher, at both visits
- Past or suspected secondary hypertension (for example narrowed kidney artery, pheochromocytoma, Cushing's syndrome, polycystic kidney disease)
- Shock
- Orthostatic hypotension (blood pressure drop on standing) with symptoms
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- <Screening Visit (V1)>
- Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the screening (Visit 1) meets the following criteria:
- For patients not currently receiving antihypertensive therapy: 140 mmHg ≤ MSSBP < 180 mmHg
- For patients receiving antihypertensive therapy : 130 mmHg ≤ MSSBP < 180 mmHg; For patients receiving antihypertensive therapy at the screening (Visit 1), those for whom the investigator determines that it is medically appropriate to temporarily discontinue their current antihypertensive treatment during the study; <Baseline Visit (V2)>; Patients with essential hypertension whose mean sitting systolic blood pressure (MSSBP) measured in the reference arm at the baseline (Visit 2) prior to randomization meets the following criteria:
- For patients without cardiovascular disease: 140 mmHg ≤ MSSBP < 180 mmHg
- For patients with cardiovascular disease, diabetes with cardiovascular disease, albuminuria, or diabetes with chronic kidney disease (CKD): 130 mmHg ≤ MSSBP < 180 mmHg
Who cannot take part
- Patients with a history of secondary hypertension or suspected secondary hypertension; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, renal hypertension, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
- Patients with blood pressure results showing MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening(V1) and baseline(V2)
- Patients with shock
- Patients with orthostatic hypotension accompanied by symptoms
Where in South Korea
- Hanyang University HospitalSoeul, South KoreaContact: Jinho Shin, MD.,PhDNot yet recruiting
About the trial
What the trial wants to find out
The objective of this clinical trial is to evaluate the antihypertensive efficacy and safety of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 with essential hypertension.
The 6 groups in the trial
- BR1400-1 + BR1400-B + BR1400-CTreatment being tested
Patients will receive tablet BR1400-1 + BR1400-B (Placebo of BR1400-2 \& BR1400-4)+ BR1400-C (Placebo of BR1400-5)
Treatment: BR1400-1, BR1400-B, and BR1400-C
- BR1400-A + BR1400-2 + BR1400-CTreatment being tested
Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-2 + BR1400-C (Placebo of BR1400-5)
Treatment: BR1400-2, BR1400-A, and BR1400-C
- BR1400-3 + BR1400-B + BR1400-CTreatment being tested
Patients will receive BR1400-3 + BR1400-B (Placebo of BR1400-2 \& BR1400-4) + BR1400-C (Placebo of BR1400-5)
Treatment: BR1400-3, BR1400-B, and BR1400-C
- BR1400-A + BR1400-4 + BR1400-CTreatment being tested
Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-4 + BR1400-C (Placebo of BR1400-5)
Treatment: BR1400-4, BR1400-A, and BR1400-C
- BR1400-A + BR1400-B + BR1400-5Other group
Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-B (Placebo of BR1400-2 \& BR1400-4) + BR1400-5
Treatment: BR1400-5, BR1400-A, and BR1400-B
- BR1400-A + BR1400-B + BR1400-CPlacebo, for comparison
Patients will receive BR1400-A (Placebo of BR1400-1 \& BR1400-3) + BR1400-B (Placebo of BR1400-2 \& BR1400-4) + BR1400-C (Placebo of BR1400-5)
Treatment: BR1400-A, BR1400-B, and BR1400-C
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Multi-center, Double-Blind, Controlled, Parallel Design, Phase II Study to Evaluate the Efficacy and Safety Administration by Doses of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension
- Plain-language title
- Testing BR1400 drugs for essential hypertension in adultsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 28 January 2026